AEON (AEON Biopharma) Long-Term Debt: $1.54 Mil (As of Mar. 2026)


AEON AEON Biopharma Inc AEON
10 GF Score
Price $0.73
! 2 Warning Signs
View Full Analysis

What is AEON Biopharma Long-Term Debt?

AEON Biopharma AEON +2.08% 10 Long-Term Debt is $1.54 Mil as of Mar. 2026. GuruFocus rates AEON with a GF Score™ of 10/100. The stock has 2 warning signs investors should review.

AEON Biopharma's Long-Term Debt for the quarter that ended in Mar. 2026 was $1.54 Mil.

AEON Biopharma's quarterly Long-Term Debt increased from Sep. 2025 ($17.05 Mil) to Dec. 2025 ($34.60 Mil) but then declined from Dec. 2025 ($34.60 Mil) to Mar. 2026 ($1.54 Mil).

AEON Biopharma's annual Long-Term Debt increased from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($11.69 Mil) and increased from Dec. 2024 ($11.69 Mil) to Dec. 2025 ($34.60 Mil).

AEON Biopharma  (AMEX:AEON) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

AEON Biopharma Long-Term Debt Related Terms

AEON Biopharma Long-Term Debt Historical Data

* Premium members only.

The historical data trend for AEON Biopharma's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AEON Biopharma Long-Term Debt Chart

AEON Biopharma Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial 70.76 60.43 0.00 11.69 34.60

AEON Biopharma Quarterly Data
Dec19 Dec20 Jun21 Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.32 15.17 17.05 34.60 1.54
AEON
10GF Score
AEON Biopharma Inc AEON
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $1.54 Mil mean?
AEON Biopharma (AEON) has a Long-Term Debt of $1.54 Mil as of Mar. 2026.
Is AEON Biopharma's Long-Term Debt too high?
AEON Biopharma's current Long-Term Debt is $1.54 Mil. Overall, AEON Biopharma has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does AEON Biopharma's Long-Term Debt compare to ZIVO and CVM?
AEON Biopharma's Long-Term Debt of $1.54 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. AEON Biopharma's current Long-Term Debt is $1.54 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AEON Biopharma stock overvalued right now?
AEON Biopharma (AEON) has a current Long-Term Debt of $1.54 Mil. The current Long-Term Debt is $1.54 Mil. AEON Biopharma's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For AEON Biopharma (AEON), the current Long-Term Debt is $1.54 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

AEON Biopharma Business Description

Address 5 Park Plaza, Suite 1750, Irvine, CA, USA, 92614
AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications. The company is advancing ABP-450 through the biosimilar regulatory pathway and holds development and commercialization rights across multiple international markets.
10GF Score

Get the complete analysis for AEON

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.73
Price